Abstract: The present invention provides a novel multianalyte LabMAP™ profiling technology that allows simultaneous measurement of multiple markers. In particular, a method is provided for diagnosing the presence of pancreatic cancer in a patient by measuring serum levels of markers in a blood marker panel comprising at least IP-10, HGF, IL-8, ?FGF, IL-12p40, TNFRI, TNFRII, Eotaxin, MCP-1 and CA 19-9, wherein a significant increase in the serum concentrations of IP-10, HGF, IL-8, ?FGF, IL-12p40, TNFRI, TNFRII, and CA 19-9 compared to healthy matched controls, and a significant decrease in the serum levels of Eotaxin and MCP-1 compared to healthy matched controls, indicates a probable diagnosis of pancreatic cancer in the patient. Also provided is a method to distinguish pancreatic cancer from chronic pancreatitis by measuring serum levels of markers in a blood marker panel.

Abstract: Provided are methods for the rapid detection of ovarian cancer. The methods employ a multiplex immunoassay to detect levels of two or more of the markers EGF, G-CSF, IL-6, IL-8, CA-125, VEGF, MCP-1, anti-IL6, anti-IL8, anti CA-125, anti-c-myc, anti-p53, anti-CEA, anti-CA 15-3, anti-MUC-1, anti-survivin, anti-bHCG, anti-osteopontin, anti-PDGF, anti-Her2/neu, anti-Akt1, anti-cytokeratin 19, cytokeratin 19, EGFR, CEA, kallikrein-8, M-CSF, FasL, ErbB2 and Her2/neu in a sample of the patient's blood, where the presence of abnormal levels of two or more of the markers indicates the presence of ovarian cancer in the patient. An array also is provided to quantitate levels of these markers in a patient's blood.